News

Article

Pharmaceutical Technology

Pharmaceutical Technology-05-02-2018
Volume42
Issue 5
Pages: 34–44

Establishing Acceptance Limits for Uniformity of Dosage Units: Part 3

The working acceptance limits for acceptance values (AV) are determined using the critical values at, for example, 95% coverage over the corresponding AV distributions. However, validity of such limits needs to be elaborated.

Yada/shutterstock.com

Part one of this article introduced the concept of sampling distribution of acceptance value (AV) in uniformity of dosage units (UDU) (1). With different sample sizes such as n= 10 and 30, their AV distributions will be different, resulting in different critical AV values (i.e., the values at the locations covering 95% of the distributions that are equal to, for example, 12.5 and 9.1 for n = 10 and 30, respectively). Such critical values will be employed as AV working limits rather than using the single compendial limit of not more than (NMT) 15 (2). 

Part two of this article described how to establish the corresponding acceptance limits for AV data for process validation batches as well as the typical characteristics of AV distributions. 

Click here to view a PDF of this article

.

Peer-Reviewed

Submitted: February 22, 2018
Accepted: March 27, 2018

About the Author

Pramote Cholayudth is validation consultant to Biolab Co., Ltd. in Thailand. He is the founder and manager of PM Consult, cpramote2000@yahoo.com.

Article Details

Pharmaceutical Technology
Vol. 42, No. 5
May 2018
Pages: 34–44

Citation

When referring to this article, please cite it as P. Cholayudth, “Establishing Acceptance Limits for Uniformity of Dosage Units: Part 3,” Pharmaceutical Technology 42 (5) 2018. 

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
 Benjamin McLeod and Sebastian Lykke Skafte Andersen go behind the headlines to examine the motivations behind recent M&A activity, tariff responses, and more.
© 2025 MJH Life Sciences

All rights reserved.